THE PROBLEM

Celiac disease (CD) is a gastrointestinal autoimmune disorder that affects millions of Americans. However, since many celiac patients do not present with gastrointestinal symptoms, diagnosis is often delayed or missed. A minimally-invasive test could identify at-risk patients and empower timely diagnosis by increasing testing compliance rates.

THE SOLUTION

Enable Biosciences’ ultrasensitive saliva assay is completely non-invasive. The saliva sample will be able to be collected in the convenience of your own home.

This product is RESEARCH USE ONLY. Contact us for more information at sales@enablebiosciences.com

QUICK FACTS

• Celiac Disease (CD) is an autoimmune disease where the body attacks itself when gluten is ingested.

• Celiac Disease can cause long lasting digestive problems and hinder your body’s intake of nutrients.

• The average time-to-diagnosis of CD is between 3.5-11 years after first observed symptoms.

• People with celiac disease have a 2x greater risk of developing coronary artery disease and a 4x greater risk of small bowel cancers. 

• Untreated celiac disease can lead to the development of other autoimmune disorders.

• While only 1% of the population of people are diagnosed with Celiac Disease, people with Type 1 Diabetes (T1D) have a 10-fold increased diagnosis risk.

THE PROBLEM:

Food allergy is a serious and growing health concern currently affecting 8% of children in the US. Blood tests based on the immunology marker IgE facilitate assessment of food allergy risks, and are required to recommend food avoidance or to implement new and innovative immunotherapies. However, current methods for allergy blood testing are expensive, require large volume phlebotomy and often result in false positives and negatives.

THE SOLUTION:

Enable Biosciences is developing an ultrasensitive assay based on the ISAP technology to detect the isotype specific antibody, IgE, for peanut, tree nuts, eggs, milk and shellfish allergens. The tests can detect multiple allergies from 1 microliter of serum while reducing the number of false positives and negatives.

This product is RESEARCH USE ONLY. Contact us for more information at sales@enablebiosciences.com

QUICK FACTS

• Food allergies affect over 26 million Americans, which includes 3 million children. 

• Every 3 minutes a person in the U.S. enters the emergency room for food-related allergic reactions (that’s over 200,000 people annually!).

• Severe allergic reactions, anaphylaxis, need to be treated within minutes to avoid death. Spring-loaded injections of epinephrine (adrenaline) can be prescribed as a preventative measure for this reason.4

• Common foods that people are allergic to include milk, eggs, peanuts, tree nuts, and shellfish.

• Current tests detect food allergies include the skin prick test, oral food challenge or blood tests. 

• Current tests can be inaccurate due to low assay specificity. 

• Current tests that can detect specific allergy markers consume large amounts of resources and sample volumes, making it expensive and unaffordable to some.

THE PROBLEM

Lyme disease (LD) is caused by Borrelia burgdorferi, a diderm bacteria transmitted via regurgitated saliva of bites of infected ticks. It usually presents as flu-like syndrome, however the classical erythema migrans (EM) rash is often missed or unrecognized. If not treated definitively during early infection, patients can suffer severe and often irreversible consequences including facial palsy, polyarthritis, neuropathy and carditis. The prevalence of LD has increased exponentially over the past 40 years due to the inexorable spread of infected ticks across the US. More than 3 million Lyme tests are performed annually. Surprisingly, in contrast to other bacterial infections, direct detection of LD bacterium genomic materials and antigens are not particularly useful in early diagnosis. This is due to the extreme scarcity of LD bacteria in the circulation. The two-tier serological testing algorithm (first-tier enzyme immunoassay followed by a second-tier Western blot) is still the mainstay of Lyme testing. However, the two-tier algorithm identifies less than 40% of early infected LD, signaling an urgent and compelling need for better diagnostics for early detection of LD. 

THE SOLUTION:

Enable Biosciences has developed a highly sensitive and specific multiplex Lyme and tick-borne disease immunoassay. The enhanced sensitivity of the assay has the potential to improve diagnosis during the early stage of disease to permit effective treatment.

This product is RESEARCH USE ONLY. Contact us for more information at sales@enablebiosciences.com

OUR PARTNERS

Tulane National Primate Research Center

QUICK FACTS

• Lyme disease (LD) is caused by the bacterium Borrelia burgdorferi transmitted to humans through the bite of infected blacklegged ticks.

• Typical symptoms include fever, headache, fatigue and a skin rash called erythema migrans, is often missed or unrecognized. 

• If the infection is not recognized and treated properly during the early stages, patients can suffer severe and often irreversible consequences including facial palsy, polyarthritis, neuropathy and carditis. 

• Over the past 40 years the prevalence of LD has increased dramatically, due to the inexorable spread of infected ticks across the US. 

• More than 3 million Lyme tests are performed every year. 

• Unfortunately, the Two-tier (first-tier enzyme immunoassay followed by a second-tier Western blot) serological testing algorithm is able to identify less than 40% of early infected LD.

THE PROBLEM

Zika virus (ZIKV) infection initially emerged as a global health concern in 2015. Since Zika and dengue (DENV) flaviviruses are found in the same geographic areas, accurate diagnosis to discriminate between the two infections is needed to optimize patient care. Fetuses of pregnant women infected by ZIKV are prone to manifest congenital Zika syndrome (CZS) including microcephaly, whereas DENV infected patients are at-risk for potentially deadly hemorrhage, circulatory and respiratory failure. Current assays fail to reliably differentiate ZIKV from DENV infection, especially in secondarily DENV infected populations. 

THE SOLUTION

Enable Biosciences developed a multiplex epitope profiling assay using variants of their ADAP assay to differentiate between ZIKV and DENV with high accuracy, sensitivity and ease of use. 

This product is RESEARCH USE ONLY. Contact us at sales@enablebiosciences.com

QUICK FACTS

• Zika is a mosquito-borne viral disease that commonly occurs in warm climates.

• Current diagnostic tests for the Zika virus (ZIKV) struggle to reliably differentiate between Zika and other flaviviruses.

• Fetuses of pregnant women infected by ZIKV are prone to congenital ZIKV syndrome, which can cause birth defects such as microcephaly.

• Prognosis and management of ZIKV and DENV differ greatly, despite both being similar flaviviruses.

• Traditional nucleic acid diagnostic tests result in many false negatives.

• Current “gold standard” diagnostic tests are potentially dangerous to perform and laborious.

Antibody Detection by Agglutination-PCR can supercharge your immunoassay development process.

Contact us to find out how you can:

Reduce sample volume required per assay

1. Detect ultralow levels of the target analyte

2. Reduce costs per test

Enable Biosciences offers:

• Assay Development Services

• Automated Workstations with Hamilton Robotics

For more information about custom reagents, kits, and fully-automated platforms to meet your immunoassay needs, contact us at sales@enablebiosciences.com